The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Key clinical trials in CLL at ASH 2020
Kerry Rogers, MD, The Ohio State University, Columbus, OH, discusses highlights in the field of chronic lymphocytic leukemia (CLL) from ASH 2020, including the Phase III Unity-CLL study (NCT02612311) comparing umbralisib plus ublituximab to obinutuzumab plus chlorambucil in patients with treatment naïve and relapsed/refractory CLL, and the Phase I/II BRUIN study (NCT03740529) investigating the Bruton’s tyrosine kinase inhibitor LOXO-305 in CLL/small lymphocytic leukemia. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
